Advertisement


Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation

2017 ASTRO Annual Meeting

Advertisement

Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).



Related Videos

Lung Cancer

Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or w...

Survivorship

James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects

James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4)....

Lymphoma

Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy

Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II fi...

Prostate Cancer
Kidney Cancer

Gerard Morton, MD, on GU Highlights: Expert Perspective

Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using...

Prostate Cancer

William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities

William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, an...

Advertisement

Advertisement



Advertisement